Pemetrexed and cisplatin combination chemotherapy is one of several choices of chemotherapy that has proven quite successful in the treatment of patients with malignant pleural mesothelioma or malignant pleural mesothelioma (MPM), but this combination can be very toxic to the body. There is no treatment and care for malignant mesothelioma cancer without any unwanted side effects.
In these journals the researchers noted that "there are two phases of the study in phase III randomized to the prognosis of mesothelioma showed benefit with the use of antifolates such as raltitrexed or Pemetrexed, when combined with cisplatin. The study has demonstrated an absolute improvement in overall survival of 2.6 and an average of 2.8 months, compared with single treatment for cisplatin. This makes a lot of institutions using cisplatin and Pemetrexed as a standard Mesothelioma Chemotherapy treatment palliative for malignant pleural mesothelioma."
Unfortunately, the combination of cisplatin and Pemetrexed produce unwanted toxic effects and it encourages researchers to study other chemotherapeutic drugs to be combined with Pemetrexed. The researchers said, "Recently, two phase II trials have evaluated the efficacy of carboplatin and will Pemetrexed in MPM. Both studies showed overall response rate of 18.6 and 25%, with a survival rate average of 12.7 and 14 months. As a continuation of these results, we conducted a retrospective analysis in patients with MPM who were treated with carboplatin and Pemetrexed in our institution."
In an effort to find a combination of mesothelioma chemotherapy with minimal toxicity and side effects, the researchers investigated further by replacing cisplatin with carboplatin when paired with Pemetrexed. Using a retrospective approach, researchers evaluated 49 cases of malignant pleural mesothelioma with a combination of carboplatin and Pemetrexed and compare the results with the data given cisplatin combination chemotherapy with Pemetrexed.
Read more »
No comments:
Post a Comment